Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire August 30, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire August 30, 2024

Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire August 29, 2024

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile August 29, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Business Wire August 29, 2024

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire August 29, 2024

Verve Therapeutics Inc. Is Being Looked Into For Securities Fraud And Impacted Shareholders Are Encouraged To Contact The Schall Law Firm

Accesswire August 29, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire August 29, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire August 29, 2024

Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

Accesswire August 28, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. Lawsuit - VERV

Accesswire August 28, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. in Securities Fraud Lawsuit

PR Newswire August 28, 2024

Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VERV

Accesswire August 28, 2024

Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire August 28, 2024

Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class Action - VERV

Accesswire August 28, 2024

The Schall Law Firm Urges Investors In Verve Therapeutics Inc To Participate In An Investigation Into Potential Securities Law Violations

Accesswire August 28, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

Accesswire August 28, 2024

VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire August 28, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Business Wire August 27, 2024

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire August 27, 2024